Comparative Study of Siltocel vs. Standard Care Regimens and FDA Advisory Committee Meeting Insights

This chapter explores a study comparing Siltocel to standard care regimens for certain patients, showcasing significant improvements in progression-free survival, especially in high-risk individuals. The FDA advisory committee meeting regarding the benefit-risk profile of Siltocel and early deaths observed during the study period is also discussed.